The evaluation and treatment of complicated skin and skin structure infections

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 717-730

  Cornia, Paul B ^a,b   Davidson, Heather L ^a   Lipsky, Benjamin A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bacterial myonecrosis; Complicated skin and skin structure infection; Necrotizing fasciitis

Indexed keywords

AZTREONAM; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CARBAPENEM; CEFAZOLIN; CEFTAZIDIME; CEFTOBIPROLE; CEPHALOSPORIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DICLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LINEZOLID; MACROLIDE; ORITAVANCIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTHRALGIA; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CLOSTRIDIUM PERFRINGENS; COMPRESSION THERAPY; CONSTIPATION; DEBRIDEMENT; DIARRHEA; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; EMPIRICISM; HUMAN; INJECTION SITE REACTION; LACTIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL IDENTIFICATION; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NECROTIZING FASCIITIS; NEPHROTOXICITY; NEUROPATHY; OPTIC NERVE DISEASE; OTOTOXICITY; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PROTHROMBIN TIME; RADIODIAGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TASTE AVERSION; THROMBOPHLEBITIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING; WOUND CARE; BACTERIAL SKIN DISEASE; BACTERIUM; DRUG EFFECT; HOSPITALIZATION; MICROBIOLOGY; SOFT TISSUE INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; FASCIITIS, NECROTIZING; HUMANS; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 41949114661     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.717     Document Type: Review

References (99)

1. Centers for Disease Control. Incidence of soft tissue infections: San Francisco General Hospital - 1996 - 2000. Morbid Mortal Weekly Rep 2001;50:381-4
2. Falagas ME, Vergitis PI. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med 2005;142:47-55
3. Swartz MN. Cellulitis. N Engl J Med 2004;350:904-912
4. Lipsky BA, Weigelt JA, Gupta V, et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 2007;28:1290-8
5. Brook I. Secondary bacterial infections complicating skin lesions. J Med Microbiol 2002;51:808-12
6. Baddour LM, Bisno AL. Non-group A beta-hemolytic streptococcal cellulitis: association with venous and lymphatic compromise. Am J Med 1985;79:155-9
7. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992;93:543-8
8. Mertz KR, Baddour LM, Bell JL, Gwin JL. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. Clin Infect Dis 1998;36:481-6
9. Miller SR, Mondry T, Reed JS, et al. Delayed cellulitis associated with conservative therapy for breast cancer. J Surg Oncol 1998;67:242-5
10. Center for Drug Evaluation and Research: Uncomplicated and complicated skin and skin structure infections - developing antimicrobial drugs for treatment. Guidance for Industry. Available from: http//www.fda.gov/cdet/ guidance/2566dft.pdf [accessed September 3, 2007]
11. Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect Dis 2005;5:501-13
12. Dinubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob Chemother 2004;53(Suppl S2):ii37-50
13. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin Microbiol Rev 2001;14(2):244-69
14. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diag Microbiol Infect Dis 2007;57:7-13
15. Naimi TS, Ledell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290(22):2976-84
16. Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9(8):978-84
17. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355(7):666-74
18. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;145(5):309-17
19. Karchmer AW. From theory to practice: resistance in Staphylococcus aureus and new treatments. Clin Microbiol Infect 2006;12(Suppl 8):15-21
20. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004;39:539-45
21. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005;352:1445-53
22. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
23. Daum RS. Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007;357:380-90
24. Moellering RC. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006;144:368-70
25. Lewis RT. Soft tissue infections. World J Surg 1998;22:146-51
26. Wong CH, Khin LW, Heng KS, et al. The LRINEC (laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med 2004;32:1535-41
27. Tan TS, Wishnow RM, Talan DA, et al. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother 1993;37(8):1580-6
28. Lipsky BA, Baker PD, Landon GC, Fernau R. Antibiotic therapy for diabetic foot infections: comparisons of two parenteral-to-oral regimens. Clin Infect Dis 1997;24(4):643-8
29. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002;34(11):1460-8
30. Lipsky BA, Armstrong DG, Citron DM, et al. Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): prospective, randomized, controlled, double-blinded, multicentre trial. Lancet 2005;366(9498):1695-703
31. Brown G, Chamberlain R, Goulding J, Clarke A. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996;14(5):547-51
32. Grayson ML, Mcdonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment for moderate-to-severe cellulitis in adults. Clin Infect Dis 2002;34(11):1440-8
33. Gentry LO, Rodriguez-Gomes G, Zeluff BJ, et al. A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections. Am J Med 1989;87(6C):57S-60S
34. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002;35(4):381-9
35. Lipsky BA, Giordano P, Choudhri S, Song J. Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. J Antimicrob Chemother 2007;60(2):370-6
36. Fass RJ, Friemer EH, Mccloskey RV. Treatment of skin and soft tissue infections with imipenem/cilastatin. Am J Med 1985;78(6A):110-2
37. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/ cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88(4):397-404
38. Kirby WM. Vancomycin therapy of severe staphylococcal infections. J Antimicrob Chemother 1984;14(Suppl D):73-8
39. Finch RG, Eliopoulos GM. Safety and efficacy of glycopeptide antibiotics. J Antimicrob Chemother 2005;55(Suppl S2):ii5-13
40. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-Sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005;25(2):253-64
41. Drew RH. Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections. Pharmacotherapy 2007;27(2):227-49
42. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-Sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infections. Ann Intern Med 1992;117:390-8
43. Riedel DJ, Weekes E, Forrest GN. Addition of rifampin in the management of native valve Staphylococcus aureus endocarditis. Presented at the 47th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago; 17 - 20 September 2007
44. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:209-22
45. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/ dalfopristin versus cefazolin, oxacillin or vancomycin. J Antimicrob Chemother 1999;44:263-73
46. Raad I, Hachem R, Hanna H, et al. Prospective, randomized study comparing quinupristin-dalfoprostin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646-9
47. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44(12):3408-13
48. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49(6):2260-6
49. Arbeit RD, Maki D, Tally FP, et al. DAPTOMYCIN 98-01 and 99-01 INVESTIGATORS: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38(12):1673-81
50. Owens RC, Lamp KC, Friederich LV, Russo R. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 2007;120(10 Suppl 1):S6-12
51. Martone WJ, Lamp KC. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry. Curr Med Res Opin 2006;22(12):2337-43
52. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections; results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49(11):4658-66
53. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50(3):862-7
54. Jauregi LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15
55. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and Enterococcus. J Drugs Dermatol 2007;6(1):97-103
56. Chirugi VA, Edelstein H, Oster SE, et al. Randomized comparison of teicoplanin IV, teicoplanin IM, and cefazolin therapy for skin and soft tissue infections caused by Gram-positive bacteria. South Med J 1994;87(9):875-80
57. Stevens DL. Teicoplanin for skin and soft tissue infections: an open study and a randomized, comparative trial versus cefazolin. J Infect Chemother 1999;5(1):40-5
58. Van Der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991;35(3):451-7
59. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004;53(2):345-55
60. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004;53(2):335-44
61. Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005;5:209-18
62. Johnston NJ, Mukhtar TA, Wright GD. Streptogramin antibiotics: mode of action and resistance. Curr Drug Targ 2002;3:335-44
63. Linden PK, Moellering RC Jr, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin Infect Dis 2001;33:1816-23
64. Moellering RC, Linden PK, Reinhardt J, et al. The efficacy and safety of quinupristin/dalfopristin for the treatment gf infections caused by vancomycin-resistant Enteroccous faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44(2):251-61
65. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis 2001;32:e83-6
66. Guay DR. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother 2003;4(8):1259-75
67. Garau J. Management of cSSTIs: the role of daptomycin. Curr Med Res Opin 2006;22(11):2079-87
68. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother 2004;53(4):669-74
69. Hair PI, Keam SJ. Daptomycin. A review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteremia. Drugs 2007;67(10):1483-512
70. Lipsky BA, Stoutenburgh U. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 2005;55:240-5
71. Krige JE, Lindfeld K, Friedrich L, et al. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 2007;23(9):2147-56
72. Fenton C, Keating GM, Curran MP. Daptomycin. Drugs 2004;64(4):445-55
73. Silverman JA, Oliver N, Andrew T, Tongchuan LI. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001;45:1799-802
74. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus bacteremia. Clin Infect Dis 2005;40(7):1058-60
75. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44(2):655-6
76. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 2007;45(5):601-8
77. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355(7):653-65
78. Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin Microbiol Infect 2001;7 Suppl 4:75-82
79. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003;47:2775-80
80. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;6:442-8
81. Mckinnon PS, Sorenson SV, Liu JZ, Itani KM. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. Ann Pharmacother 2006;6:1017-23
82. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001;285:1291
83. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007;27:1189-97
84. Gonzales RD, Schreckenberger PC, Graham MB, et al. Infection due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357:1179
85. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8
86. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis 2006;43:518-24
87. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
88. Ward KE, Mersfelder TL, Laplante KL. Oritavancin: an investigational glycopeptide antibiotic. Expert Opin Invest Drugs 2006;15:417-29
89. Widmer AF. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:656-8
90. Noel GJ, Strauss RS, Amsler K, et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008;52:37-44
91. Noel GJ, Bush K, Bagchi P, et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008;46:647-55
92. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001;161:61-5
93. Brandt MM, Corpron CA, Wahl WL. Necrotizing soft-tissue infections: a surgical disease. Am Surg 2000;66:967-70
94. Stamenkovic I, Lew PD. Early recognition of potentially fatal necrotizing fasciitis. The use of frozen section biopsy. N Engl J Med 1984;310:1689-93
95. Mchenry CR, Piotrowski JJ, Petrinic D, Malangoni MA. Determinants of mortality for necrotizing soft-tissue infections. Ann Surg 1995;221:558-65
96. Bilton BD, Zibari GB, McMillan RW, et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg 1998;64(5):397-400
97. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg 1996;224(5):672-83
98. Armstrong DG, Nguyen HC. Improvement in healing with aggressive edema reduction after debridement of foot infection in persons with diabetes. Arch Surg 2000;135(12):1405-19
99. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345(19):1359-67